科研之友
微信
新浪微博
Facebook
分享链接
摘要
【Abstract】 Objective To investigate the short-term efficacy and safety of albumin-bound paclitaxel combined with nedaplatin followed by concurrent radiotherapy in treatment of stage Ⅲ massive cervical cancer. Methods The clinical data of 84 patients with massive cervical cancer admitted to Harbin Medical University Cancer Hospital from April 2019 to April 2020 were retrospectively analyzed. According to the different treatment regimens, patients were divided into the observation group and the control group, each with 42 cases. The observation group received albumin - bound paclitaxel combined with nedaplatin followed by concurrent radiotherapy, and the control group received solvent - based paclitaxel combined with nedaplatin followed by concurrent radiotherapy. The short - term efficacy and adverse reactions of the two groups were compared. Results The partial remission (PR) rate of the observation group and the control group at 1 month of treatment was 92.9% (39/42) and 35.7% (15/42), respectively, and the difference was statistically significant (χ2 = 29.867, P < 0.01). The complete remission (CR) rate of the observation group and the control group at 1 month after treatment was 59.5% (25/42) and 38.1% (16/42), respectively, and the difference was statistically significant (χ2 = 3.859, P = 0.049). The incidence of diarrhea of the observation group was lower than that of the control group [33.33% (14/42) vs. 54.8% (23/42)], and the difference was statistically significant (χ2 = 3.913, P = 0.048). There were no statistical differences in the incidence of hematological adverse reactions and abnormal liver and kidney functions between the two groups (all P > 0.05). Conclusion The albumin-bound paclitaxel combined with nedaplatin followed by concurrent radiotherapy have a good short - term efficacy in treatment of stage Ⅲ massive cervical cancer, and the adverse reactions are tolerable. ? 2021 Chinese Medical Association Publishing House Co. Ltd.
